• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Lyra Therapeutics names new chief medical officer

February 17, 2021 By Sean Whooley

Lyra Therapeutics (NSDQ:LYRA) announced today that it appointed Dr. Robert Kern as its new chief medical officer.

Kern will remain in his current position as the George A. Sisson Professor and Chair, Department of Otolaryngology – Head and Neck Surgery at the Northwestern University Feinberg School of Medicine while operating as Lyra’s CMO, according to a news release.

“We are excited to welcome Dr. Kern, who is a renowned physician in the ENT field and a world-leading expert in chronic rhinosinusitis, to the Lyra team as our chief medical officer, to oversee the development of our clinical pipeline,” Lyra Therapeutics CEO Maria Palasis said in the release. “Dr. Kern has a proven track record of global leadership in otolaryngology, in both academic research and clinical rhinology, that we believe will prove invaluable to Lyra’s successful development of LYR-210 and LYR-220.”

Kern was previously the president of the American Rhinologic Society and is the current president of the International Society of Inflammation & Allergy of the Nose. The 30-year veteran of the ENT field joined the Northwestern faculty more than 20 years ago and was appointed as the otolaryngology department chair in 2006.

He takes over the Watertown, Mass.-based company developing drug and delivery solutions for patients with ENT diseases, including LYR-210, which is designed to deliver up to six months of continuous anti-inflammatory drug therapy to the sinonasal passages for treating chronic rhinosinusitis (CRS) in those who have not undergone surgery for the disease.

LYR-220 is under development for CRS patients who have undergone a prior surgery and have persistent disease, while Lyra’s XTreo platform, which includes a drug administered through a bioresorbable polymeric matrix, is also being developed to address other disease areas with precise, consistent and local delivery through a single administration.

“I know firsthand the enormous need for new treatment options for CRS patients, and I am enthusiastic to guide the next phase of clinical development for LYR-210 and LYR-220,” Kern said. “Lyra established a clear proof of concept for LYR-210 with the recent positive LANTERN Phase 2 results, and I am pleased to join the dynamic leadership team to help advance Lyra’s next stage of growth as we work together to address the needs of underserved patients chronically suffering with CRS.”

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Otolaryngology Ear, Nose & Throat, Pharmaceuticals Tagged With: Lyra Therapeutics, Personnel Moves

IN CASE YOU MISSED IT

  • BriaCell Therapeutics closes $25M offering
  • ICU Medical dips despite Street-beating Q4
  • 8 drug delivery innovations you need to know
  • Axonics acquires Contura and its Bulkamid bulking agent for $235M
  • Lilly to add Welldoc app to future insulin pen

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Footer

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Design & Outsourcing
Medical Tubing + Extrusion

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery News
Advertise with us
About
Contact us
Privacy
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2021 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS